In contrast, studies including hematologic malignancies where high CXCR4 expression is found, like non-Hodgkin-lymphoma, multiple myeloma, chronic lymphocytic leukaemia and acute myeloid leukaemia, depict the potential of [68Ga]Ga-Pentixafor PET/CT as a diagnostic marker for these malignancies [211]. Here, CXCR4 is linked to B-cell chronic lymphocytic leukemia.